SAMDaily.us | PRESOL | 65 | Human primary CD34+ Hematopoietic stem and Progenitor cells

SAMDAILY.US - ISSUE OF AUGUST 20, 2020 SAM #6839
SOLICITATION NOTICE

65 -- Human primary CD34+ Hematopoietic stem and Progenitor cells

Notice Date: 8/18/2020 10:30:51 AM
Notice Type: Combined Synopsis/Solicitation
NAICS: 325413 — In-Vitro Diagnostic Substance Manufacturing
Contracting Office: FDA OFFICE OF ACQ GRANT SVCS ROCKVILLE MD 20857 USA
ZIP Code: 20857
Solicitation Number: FDA-SOL-1233197
Response Due: 9/1/2020 10:00:00 AM
Archive Date: 09/16/2020
Point of Contact: Roosevelt Walker, Phone: 8705437405
E-Mail Address: roosevelt.walker@fda.hhs.gov
(roosevelt.walker@fda.hhs.gov)
Description: The U.S. Food and Drug Administration (FDA), Center for Biologics Evaluation and Research (CBER) / Division of Cell and Gene Therapy (DCGT), Office of Cellular, Tissue and Gene Therapy requires Human primary CD34+ hematopoietic stem and progenitor cells to have assessed identity and characterization of gene and cell therapy products to perform critical path research for its mission to develop and promote technology to regulate cellular and genetic therapeutics.
Web Link: SAM.gov Permalink
(https://beta.sam.gov/opp/883cad98d13c4a1386c91d9184c8f1f2/view)
Place of Performance: Address: Silver Spring, MD 20993, USA; Zip Code: 20993; Country: USA
Record: SN05763760-F 20200820/200818230205 (samdaily.us)
Source: SAM.gov Link to This Notice
(may not be valid after Archive Date)

| FSG Index | This Issue's Index | Today's SAM Daily Index Page |